Matthew L. Posard - Net Worth and Insider Trading
Matthew L. Posard Net Worth
The estimated net worth of Matthew L. Posard is at least $8 Million dollars as of 2024-12-27. Matthew L. Posard is the Sr VP & General Manager of Illumina Inc and owns about 30,858 shares of Illumina Inc (ILMN) stock worth over $4 Million. Matthew L. Posard is the Director of Halozyme Therapeutics Inc and owns about 69,874 shares of Halozyme Therapeutics Inc (HALO) stock worth over $3 Million. Matthew L. Posard is also the Director of Nautilus Biotechnology Inc and owns about 150,000 shares of Nautilus Biotechnology Inc (NAUT) stock worth over $264,000. Besides these, Matthew L. Posard also holds Talis Biomedical Corp (TLIS) , DermTech Inc (DMTKQ) . Details can be seen in Matthew L. Posard's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Matthew L. Posard has not made any transactions after 2024-08-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Matthew L. Posard
Matthew L. Posard Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Matthew L. Posard owns 7 companies in total, including DermTech Inc (CNACU) , Halozyme Therapeutics Inc (HALO) , and Cardiff Oncology Inc (CRDF) among others .
Click here to see the complete history of Matthew L. Posard’s form 4 insider trades.
Insider Ownership Summary of Matthew L. Posard
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
CNACU | DermTech Inc | 2020-06-17 | director |
HALO | Halozyme Therapeutics Inc | 2024-08-14 | director |
CRDF | Cardiff Oncology Inc | 2015-08-21 | Chief Commercial Officer |
2013-05-30 | Sr VP & GM & Consumer Genomics | ||
2021-02-17 | director | ||
2021-01-11 | director | ||
2021-12-01 | director |
Matthew L. Posard Latest Holdings Summary
Matthew L. Posard currently owns a total of 5 stocks. Among these stocks, Matthew L. Posard owns 30,858 shares of Illumina Inc (ILMN) as of May 30, 2013, with a value of $4 Million and a weighting of 53.52%. Matthew L. Posard owns 69,874 shares of Halozyme Therapeutics Inc (HALO) as of August 14, 2024, with a value of $3 Million and a weighting of 43%. Matthew L. Posard also owns 150,000 shares of Nautilus Biotechnology Inc (NAUT) as of December 1, 2021, with a value of $264,000 and a weighting of 3.39%. The other 2 stocks Talis Biomedical Corp (TLIS) , DermTech Inc (DMTKQ) have a combined weighting of 0.09% among all his current holdings.
Latest Holdings of Matthew L. Posard
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ILMN | Illumina Inc | 2013-05-30 | 30,858 | 135.18 | 4,171,384 |
HALO | Halozyme Therapeutics Inc | 2024-08-14 | 69,874 | 47.96 | 3,351,157 |
NAUT | Nautilus Biotechnology Inc | 2021-12-01 | 150,000 | 1.76 | 264,000 |
TLIS | Talis Biomedical Corp | 2021-02-17 | 4,167 | 1.70 | 7,084 |
DMTKQ | DermTech Inc | 2021-01-11 | 86,863 | 0.00 | 0 |
Holding Weightings of Matthew L. Posard
Matthew L. Posard Form 4 Trading Tracker
According to the SEC Form 4 filings, Matthew L. Posard has made a total of 0 transactions in Illumina Inc (ILMN) over the past 5 years. The most-recent trade in Illumina Inc is the sale of 2,836 shares on May 30, 2013, which brought Matthew L. Posard around $200,789.
According to the SEC Form 4 filings, Matthew L. Posard has made a total of 3 transactions in Halozyme Therapeutics Inc (HALO) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Halozyme Therapeutics Inc is the sale of 29,881 shares on August 14, 2024, which brought Matthew L. Posard around $2 Million.
According to the SEC Form 4 filings, Matthew L. Posard has made a total of 1 transactions in Nautilus Biotechnology Inc (NAUT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Nautilus Biotechnology Inc is the acquisition of 50,000 shares on December 1, 2021, which cost Matthew L. Posard around $225,500.
More details on Matthew L. Posard's insider transactions can be found in the Insider Trading History of Matthew L. Posard table.Insider Trading History of Matthew L. Posard
- 1
Matthew L. Posard Trading Performance
GuruFocus tracks the stock performance after each of Matthew L. Posard's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Matthew L. Posard is -8.44%. GuruFocus also compares Matthew L. Posard's trading performance to market benchmark return within the same time period. The performance of stocks bought by Matthew L. Posard within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Matthew L. Posard's insider trading performs compared to the benchmark.
Performance of Matthew L. Posard
Matthew L. Posard Ownership Network
Matthew L. Posard Owned Company Details
What does DermTech Inc do?
Who are the key executives at DermTech Inc?
Matthew L. Posard is the director of DermTech Inc. Other key executives at DermTech Inc include Chief Commercial Officer Todd Michael Wood , director & Chief Executive Officer John Dobak , and Chief Operating Officer Claudia Ibarra .
DermTech Inc (CNACU) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of DermTech Inc (CNACU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of DermTech Inc (CNACU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
DermTech Inc (CNACU)'s detailed insider trading history can be found in Insider Trading Tracker table.
DermTech Inc Insider Transactions
Matthew L. Posard Mailing Address
Above is the net worth, insider trading, and ownership report for Matthew L. Posard. You might contact Matthew L. Posard via mailing address: 11099 N. Torrey Pines Road, Suite 100, La Jolla Ca 92037.